proved that tumor regression in the humanized nasopharyngeal cancer (NPC) mouse model was achieved by designing CAR NK cells harboring anti-PD-L1 properties and synergized anticancer effects with a checkpoint inhibitor, nivolumab (106). Here, CD274 is linked to nasopharyngeal carcinoma.